Obinutuzumab: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Obinutuzumab, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The two known uses are related to an approved indication by disease category; they are not listed here as approved.
Quick overview
Item
Content
New predicted indications
None (all traceable model candidates are known uses)
Known uses among model candidates
2
Evidence level
Not applicable
Canada Market Status
Marketed (marketed DINs: 1 of 1)
Number of DINs
1 (marketed: 1)
Known uses among the model’s candidates
Approved (supported by a licence or label)
Indication
Source
none
none
Related to an approved indication (same disease category)
Indication
Approved category
pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma
cll
chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation
cll
Relations recorded in the knowledge graph (no approval found)
Indication
none
Canada Market Information
Licence
Product
Dosage form
Status
02434806
GAZYVA
Valid
Cytotoxicity
Item
Content
Cytotoxicity Classification
Targeted therapy / immunotherapy (anti-CD20 monoclonal antibody), not a conventional cytotoxic agent
Myelosuppression Risk
Please refer to the package insert warnings and precautions
Emetogenicity Classification
Please refer to the package insert warnings and precautions
Monitoring Items
Please refer to the package insert; blood counts and routine laboratory monitoring are typical for anti-CD20 therapy
Handling Protection
Please refer to the package insert and local institutional policy for handling antineoplastic biologics
Safety Considerations
Package-insert warnings and contraindications were not compiled for this report. Please refer to the package insert for these.
Drug Interactions: The interaction database returned 81 interacting drugs. Examples of the main ones:
Moderate: strontium chloride Sr-89, roflumilast, chloramphenicol, zidovudine, alemtuzumab, alefacept, anakinra, azathioprine, canakinumab, and several vaccines (tetanus toxoid, anthrax, live cholera)
Many of these are immunosuppressive or myelosuppressive agents, or vaccines. This points to additive immunosuppression, additive myelosuppression, and vaccine-response concerns.
Disclaimer
This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.